Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Randomized Phase III Trial Comparing Conventional-Dose Chemotherapy Using Paclitaxel, Ifosfamide, and Cisplatin (TIP) With High-Dose Chemotherapy Using Mobilizing Paclitaxel Plus Ifosfamide Followed by High-Dose Carboplatin and Etoposide (TI-CE) as First Salvage Treatment in Relapsed or Refractory Germ Cell Tumors

NCT02375204 is registered in ClinicalTrials.gov with Alliance for Clinical Trials in Oncology as lead sponsor.

NCT NCT02375204
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02375204 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Randomized Phase III Trial Comparing Conventional-Dose Chemotherapy Using Paclitaxel, Ifosfamide, and Cisplatin (TIP) With High-Dose Chemotherapy Using Mobilizing Paclitaxel Plus Ifosfamide Followed by High-Dose Carboplatin and Etoposide (TI-CE) as First Salvage Treatment in Relapsed or Refractory Germ Cell Tumors
Lead sponsor
Alliance for Clinical Trials in Oncology
Phase
Phase 3
Overall status
Active, not recruiting
Start date
August 6, 2015
Completion date
June 1, 2031
Enrollment
420 (actual)
Sites
125

Conditions

As the registry lists them; a condition with its own page is linked.

childhood teratoma, choriocarcinoma, extragonadal seminoma, germ cell tumor, germinoma, malignant germ cell neoplasm, mixed germ cell tumor, non-seminomatous germ cell tumor, seminoma, teratoma, yolk sac tumor